Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Sage Therapeutics stops Parkinson’s drug work after data misses, stock drops - Boston Business Journal
Sage Therapeutics stops Parkinson’s drug work after data misses, stock drops - The Business Journals
Sage Therapeutics stops Parkinson's drug work after data misses, stock drops - Boston Business Journal - The Business Journals
Sage Therapeutics stops Parkinson's drug work after data misses, stock drops - Boston Business Journal - Boston Business Journal
Sage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $15.63 - MarketBeat
RBC maintains stock target on Sage Therapeutics post-trial results - Investing.com
Sage Therapeutics shares plummet 20% on dalzanemdor update, Truist maintains hold - Investing.com South Africa
Sage Therapeutics shares plummet 20% on dalzanemdor update, Truist maintains hold - Investing.com
BofA downgrades Sage to underperform, cites failed Parkinson's study (NASDAQ:SAGE) - Seeking Alpha
William Blair on Sage Therapeutics (SAGE): 'we have difficulty envisioning what additional data could be generated to ... - StreetInsider.com
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
×